Recruiting PHASE2 INTERVENTIONAL 2-arm NCT07254585

SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

An Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of SYS6010 Combined With Enlonstobart in the Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

Conditions Head and Neck Squamous Cell Carcinoma

Interventions Enlonstobart injection SYS6010 injection

Updated 2 times since 2025 Last updated: Jan 23, 2026 Started: Dec 18, 2025 Primary completion: Jun 30, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Head and Neck Squamous Cell Carcinoma and is currently actively recruiting participants. CSPC Megalith Biopharmaceutical Co.,Ltd. leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC Megalith Biopharmaceutical Co.,Ltd.

Data source: CSPC Megalith Biopharmaceutical Co.,Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China